Characterization of genetic predisposition and autoantibody profile in atypical haemolytic–uraemic syndrome
Bahadur Singh Gurjar(National Institute of Immunology), Arvind Bagga(All India Institute of Medical Sciences), Vineeta Bal(Indian Institute of Science Education and Research Pune), Himanshi Saini(All India Institute of Medical Sciences), Arvind Sahu(National Centre for Cell Science), Tholu Manikanta Sriharsha(National Centre for Cell Science), Angika Bhasym(Manipal Academy of Higher Education), Mamta Puraswani(All India Institute of Medical Sciences), Anna George(Hoshi University), Amita Sharma(Harvard University), Priyadarshini Chatterjee(Regional Centre for Biotechnology), Pankaj Hari(Indian Council of Medical Research), Anita Verma(Unknown), Aditi Sinha, Prasenjit Guchhait(Regional Centre for Biotechnology), Savit B. Prabhu(Christian Medical College, Vellore), Priyanka Khandelwal(Chacha Nehru Bal Chikitsalaya), Savita Saini(All India Institute of Medical Sciences), Satyajit Rath(National Institute of Immunology)
Cited by 18
Related Papers
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome
|Clinical Journal of the American Society of Nephrology|2010|203